Pharmacotherapy of Parkinson's disease in Germany

Journal of Neurology

Volumn 252, Issue 8, 2005, Pages 926-935

  Moller J C ^a   Korner Y ^b   Dodel, R C ^c   Meindorfner, C ^b   Stiasny Kolster, K ^a   Spottke, A ^c   Kruger H P ^b   Oertel, W H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Depression; Dopamine agonist; Levodopa; Sleep attack

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; APOMORPHINE; BENZATROPINE; BIPERIDEN; BROMOCRIPTINE; BUDIPINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DECARBOXYLASE INHIBITOR; DIAZEPINE DERIVATIVE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; METIXENE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OXAZEPINE DERIVATIVE; PERGOLIDE; PHENOTHIAZINE DERIVATIVE; PRAMIPEXOLE; ROPINIROLE; SEDATIVE AGENT; SELEGILINE; SPASMOLYTIC AGENT; TRIHEXYPHENIDYL; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOPAMINERGIC SYSTEM; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; SEDATION; SIDE EFFECT; SLEEP;

AGE FACTORS; AGED; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; ODDS RATIO; PARKINSON DISEASE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 23944460596     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0784-1     Document Type: Article

References (28)

1. Askmark H, Antonov K, Aquilonius SM (2003) The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption - a nation-wide perspective in Sweden. Parkinsonism Relat Disord 9:271-276
2. Brandstädter D, Oertel WH (2003) Depression in Parkinson's disease. Adv Neurol 91:371-381
3. Dodel RC, Berger K, Oertel WH (2001) Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 19:1013-1038
4. Dodel RC, Singer M, Köhne-Volland R, Szucs T, Rathay B, Scholz E, Oertel WH (1998) The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 14:299-312
5. Donnan PT, Steinke DT, Stubbings C, Davey PG, MacDonald TM (2000) Selegiline and mortality in subjects with Parkinson's disease. Neurology 55:1785-1789
6. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427-442
7. Bundesverband der pharmazeutischen Industrie (2000) Rote Liste. Rote Liste Verlag, Weinheim
8. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540-545
9. Körner Y, Meindorfner C, Möller JC, Stiasny-Kolster K, Haja D, Cassel W, Oertel WH, Krüger HP (2004) Predictors of sudden onset of sleep. Mov Disord 19:1279-1284
10. Leoni O, Martignoni E, Cosentino M, Michielotto D, Calandrella D, Zangaglia R, Riboldazzi G, Oria C, Lecchini S, Nappi G, Frigo G (2002) Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf 11:149-157
11. LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M (1999) Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 16:59-69
12. Lienert GA, Krauth J (1974) Die Konfigurationsanalyse. IX. Auswertung multivariater klinischer Untersuchungspläne (Teil 1). Zeitschr Klin Psychol Psychother 22:3-17
13. Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J, Hutchinson WD, Dostrovsky JO (1995) Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 346:1383-1387
14. Meissner W, Trottenberg T, Klaffke S, Paul G, Kuhn AA, Arnold G, Einhäupl KM, Kupsch A (2001) Apomorphine therapy versus deep brain stimulation. Clinical and economic aspects in patients with advanced Parkinson's disease. Nervenarzt 72:924-927
15. Moro E, Scerrati M, Romito LMA, Roselli R, Tonali P, Albanese A (1999) Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 53:85-90
16. Klinische "Leitlinien" der Deutschen Gesellschaft für Neurologie (2003) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, Stuttgart
17. Oertel WH, Quinn N (2002) Parkinsonism. In: Brandt T, Diener HC, Caplan LR (eds) Neurological disorders: course and treatment. Academic Press, San Diego, pp 1021-1079
18. Oertel WH, Quinn NP (1996) Parkinsonism. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds) Neurological Disorders - Course and Treatment. Academic Press, San Diego, pp 715-772
19. Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Mov Disord 56:S1-S88
20. Pfeiffer RF (2003) Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 2:107-116
21. Schwabe U (2001) Parkinsonmittel. In: Schwabe U, Paffrath D (eds) Arzneiverordnungsreport 2001. Springer, Berlin, pp 591-596
22. Shabnam GN, Th C, Kho D, H R, Ce C (2003) Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev: CD003465
23. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF (2002) Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey. Parkinsonism Relat Disord 8:277-284
24. Singer C (1998) Urinary dysfunction in Parkinson's disease. Clin Neurosci 5:78-86
25. Singer C, Weiner WJ, Sanchez-Ramos JR (1992) Autonomic dysfunction in men with Parkinson's disease. Eur Neurol 32:134-140
26. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP (2001) Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 13:187-196
27. Spottke EA, Martin R, Berger K, Machat O, Oertel WH, Dodel RC (2002) Healthcare utilization and economic impact of Parkinson's disease. Mov Disord 17(Suppl 5):S142
28. Spottke EA, Reuter M, Machat B, Bornschein B, Campenhausen S, Berger K, Koehne-Volland RK, Rieke J, Simonow A, Brandstädter D, Siebert U, Oertel WH, Dodel RD. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics: in press